Skip to main content
Premium Trial:

Request an Annual Quote

AACR: High-Throughput Compound Testing

Premium

At the American Association for Cancer Research's annual meeting in Chicago last week, the Novartis Institute for BioMedical Research's William Sellers spoke about the importance of finding the right combinations of drugs to treat different kinds of cancer. "One drug is never enough," he said during his talk at the opening plenary session.

Finding the right combinations can be "daunting," he added. But companies like Novartis are developing ways to make the process more efficient. Sellers showed a short clip of a high-throughput robotic system that he says can test 1,500 compounds on 600 different cancer cell lines in just three months, in order to see if these compounds have any therapeutic effect.

(Video courtesy of William Sellers)

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.